A Breakthrough in Hydrogel Technology
Diabetic ulcers are an example of costly, chronic wounds that often result in limb amputations. Diabetic ulcers are estimated to cost $78 billion per year in the United States alone, they lead to 80% of non-traumatic amputations, and every 20 seconds a limb is lost to a diabetic ulcer that would not heal. Better treatment options are desperately needed. Chronic wounds suffer from high levels of inflammation which impairs the natural healing process. Wound dressings currently available do not address the inflammation problem. Currently available wound dressings are also not capable of sustained therapeutic delivery.
GelSana’s novel hydrogel technology helps reduce inflammation at the wound site, providing decreased healing time in diabetic animal trials. Improved healing would reduce the risk of infection and amputation. Our novel hydrogels have superior handling properties; they are extrudable yet highly elastic and stretchable. They gently adhere to the surrounding healthy tissue while not adhering to a moist wound bed. These hydrogels will donate moisture to wounds that could benefit from this and they are able to accept moisture from wounds with high exudate production. GelSana hydrogels are also capable of providing sustained release of therapeutics to the wound bed over time, promoting even additional improvements in healing.
Hydrogels with novel chemistry that gently adhere to surrounding healthy tissues while protecting the wound, that reduce inflammation to lead to improved healing, and that are capable of sustained drug delivery over time to the wound bed.